{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","slug":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"SGI-110 Dose Escalation","genericName":"SGI-110 Dose Escalation","slug":"sgi-110-dose-escalation","indication":"Other","status":"phase_1"},{"name":"Contrave","genericName":"Contrave","slug":"contrave","indication":"Other","status":"marketed"},{"name":"Azacitadine","genericName":"Azacitadine","slug":"azacitadine","indication":"Other","status":"phase_3"},{"name":"Cabrilizumab","genericName":"Cabrilizumab","slug":"cabrilizumab","indication":"Other","status":"discontinued"},{"name":"Lupron","genericName":"Lupron","slug":"lupron","indication":"Other","status":"marketed"},{"name":"PARP Inhibitor BGB-290","genericName":"PARP Inhibitor BGB-290","slug":"parp-inhibitor-bgb-290","indication":"Other","status":"phase_1"},{"name":"Rabbit antithymocyte globulin","genericName":"Rabbit antithymocyte globulin","slug":"rabbit-antithymocyte-globulin","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"aMIL","genericName":"aMIL","slug":"amil","indication":"Lymphoma (personalized neoantigen therapy)","status":"marketed"},{"name":"Cisplatin + Gemcitabine","genericName":"Cisplatin + Gemcitabine","slug":"cisplatin-gemcitabine","indication":"Advanced or metastatic urothelial carcinoma","status":"phase_3"},{"name":"Taxotere","genericName":"Taxotere","slug":"taxotere","indication":"Carcinoma of breast","status":"marketed"},{"name":"Xeloda","genericName":"Xeloda","slug":"xeloda","indication":"Lymph Node Positive Colorectal Carcinoma","status":"marketed"}]}],"pipeline":[{"name":"SGI-110 Dose Escalation","genericName":"SGI-110 Dose Escalation","slug":"sgi-110-dose-escalation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Contrave","genericName":"Contrave","slug":"contrave","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"aMIL","genericName":"aMIL","slug":"amil","phase":"marketed","mechanism":"aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.","indications":["Lymphoma (personalized neoantigen therapy)"],"catalyst":""},{"name":"Azacitadine","genericName":"Azacitadine","slug":"azacitadine","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cabrilizumab","genericName":"Cabrilizumab","slug":"cabrilizumab","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cisplatin + Gemcitabine","genericName":"Cisplatin + Gemcitabine","slug":"cisplatin-gemcitabine","phase":"phase_3","mechanism":"Cisplatin and gemcitabine work together as a chemotherapy combination to damage cancer cell DNA and inhibit nucleotide synthesis, leading to cell death.","indications":["Advanced or metastatic urothelial carcinoma","Non-small cell lung cancer","Pancreatic cancer","Ovarian cancer"],"catalyst":""},{"name":"Lupron","genericName":"Lupron","slug":"lupron","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PARP Inhibitor BGB-290","genericName":"PARP Inhibitor BGB-290","slug":"parp-inhibitor-bgb-290","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rabbit antithymocyte globulin","genericName":"Rabbit antithymocyte globulin","slug":"rabbit-antithymocyte-globulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Taxotere","genericName":"Taxotere","slug":"taxotere","phase":"marketed","mechanism":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","indications":["Carcinoma of breast","Malignant tumor of head and/or neck","Malignant tumor of prostate","Malignant tumor of stomach","Metastatic Breast Carcinoma"],"catalyst":""},{"name":"Xeloda","genericName":"Xeloda","slug":"xeloda","phase":"marketed","mechanism":"Thymidylate synthase","indications":["Lymph Node Positive Colorectal Carcinoma","Malignant tumor of stomach","Metastasis from malignant tumor of colon","Metastatic Breast Carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPSTZfQkR4TEtndFY2MklfVkNLZXZGSEI1RVhycGdFcXJ0b01EV0h6ZXdHTDlRQjRTNzY4Rnd0YnVBY3B2UlZxMTZ4dmZDSW9UUDJYWjNVUkE5ODBoZTA2MHpNTHJubXpCQUlMSEZKdnBOOXktMkQ5MGt2YmJEellndjliTk9VVV9ieHJMYzlOUmVQaE5aSUN5VlhRUEZPOTdQaEpDVDZXN1VZOW95RUU4SkxCeWZoNmtlOTdsZ29pWlgtZlY4MnBFazY4bEE5S25RTktMZnJldmo4SXpQS0xORjZOZFpBMTQ?oc=5","date":"2025-12-22","type":"pipeline","source":"Johns Hopkins Medicine","summary":"Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias - Johns Hopkins Medicine","headline":"Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPdGlRVUtaT3RZc0lrTV9QV2pVU1A5S1NZcExaU1RBN3h4YmZlY09ITHdwTS1KYjZLcHZIWU5TUXRwdHJvVWFSVlZXTThzbzJEeFZKczhSN2VrdW9kZ3Iwb25iTGtJZ3hfUVRraDlqZlNKUGYyX2xESDg0MG90djVYV2lwRWFQNkdCUVU2Zl81VlhLMzZOWi1KSzN2YURodmpoWHhzN1VXN0syMFdfcUkxXzVLbHZiUDVKM3RqMUFCdkhUeHh3R2R2eFBQY2xuNXNzLUppVnMydXZCSzE5?oc=5","date":"2025-09-18","type":"pipeline","source":"PR Newswire","summary":"Break Through Cancer Launches Largest-Ever Investment in Pediatric Osteosarcoma Research - PR Newswire","headline":"Break Through Cancer Launches Largest-Ever Investment in Pediatric Osteosarcoma Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNUmxWaWRWX01KNnV4Z010c0NKbTJSemNOakNBakN2TENjMGJ3ZDB2Ung2dUVCbVNPUmFFWmlEU3h2R3hZR0llcTh0RlpHNlBJUHNZNERkVnhVamJJODYyTEFRNEdLcjU4SmdFcXp4ZzJxMHAtc254SFY1d0JMTnBVbDBHYnZNcDlXUmdBTU5STERPajFmR01vMmhQYzhicWpTVVpWeF9xREk2aDJ3dGhkZjNSU2dYWDQtSHY3R1FsMmJiR2lyTVJRNEJfLU9zeE9wRWFMYVQzeWYwaFhad3E1VHQ0cm9POXBxVE00RXNZcE52NHVMemdBR2RhVWJhckpnZWtPeklKeXNPVGlLdHUzY3pfdFk5UmJUTjJNLWtRWVdhVnNpbnR0d01lcWI0NUI5bl9SWmlPdFFDQTdhU3dnWGx5ZFBoSjB6Y012NWdTcWViSUE?oc=5","date":"2025-09-08","type":"trial","source":"Johns Hopkins Medicine","summary":"First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma - Johns Hopkins Medicine","headline":"First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Comb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPbDg3OWpoVUNVbi1JWnR6RENRbkFnZ2l3YVAwUVJxeTFxUHRSNy12TFl1Ql9CWnljcUEwdG1rVmRlSl9VSi03SWkwdWVZZVc2RVJFdGs0QmR0OFZ2eXpZa3ZqbEVsd2Njel96Zmw3bWVUUW96S2RxbFAtVXB1Q2FUN2xIb0Nlb2JFT3A4b184eG1CaG9qQ3MwN25taHluaFQwWHBPdnRR?oc=5","date":"2025-06-03","type":"pipeline","source":"Medscape","summary":"Will Federal Cuts Affect mRNA Cancer Vaccine Research? - Medscape","headline":"Will Federal Cuts Affect mRNA Cancer Vaccine Research?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPLS1YQXJDeHpER1Nwa043QkEwbEpvUFJqeFBsX21EV194REdCOFNqaUZUMFBxUVhtXzhEQWZHY0paVG1yLVRGTDhKSy1GcGNfeWVfYWhyRzFBTHF5OGk1MHl1WVlOUWRBMFlpVy1MbGxkbURtcDhZVExIMnU4bVZmNWVBUUI3LUNzQmhFTFJrSm41NWxQT0V5N2JoRUFIMks1Y3htS3l4OVg1Wm92aDhkQUNNQktTVnoyTzkzY3pSMS1JajZwVUZRLXctc2hEOUxnbUZYWlpHOWVCdGtRS1pyWGVWTVZDcTR3QnhTcg?oc=5","date":"2025-04-21","type":"pipeline","source":"Johns Hopkins Medicine","summary":"Older Adults Respond Well to Immunotherapy Despite Age-Related Immune System Differences - Johns Hopkins Medicine","headline":"Older Adults Respond Well to Immunotherapy Despite Age-Related Immune System Differences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNV1FLZnY5Y0NHdWJPQ2N1Q3ZVTFdMWWs5aTQteTRYd0dEX3hSMFQtdjI0ZEJLZjlKa0VwN2tveXpKeUUzcTBHMVRyaFJSM05KYk4tZUd3YWtfQ0pZdnVjV1QzYU9VWlMzT3N6clVvTjR2Si01LW9tbEFGazIxOXpLQjZR?oc=5","date":"2023-12-12","type":"pipeline","source":"Johns Hopkins Medicine","summary":"From the Director - Johns Hopkins Medicine","headline":"From the Director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE01alRvWWFYV2Jsa3RmZjhraEtlWkl1MzdTanI0LTlrX3BvSmRwc09KZUhrSVpLZDk3SnFPRVcxTXd3WWxzQlBkZU1kZi0zbkZsdl9VSnBEb0k?oc=5","date":"2023-11-17","type":"pipeline","source":"The Cancer Letter","summary":"Michelle Rudek, director of Analytical Pharmacology Shared Resource at Hopkins, dies at 51 - The Cancer Letter","headline":"Michelle Rudek, director of Analytical Pharmacology Shared Resource at Hopkins, dies at 51","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5QMkFwM3VWOWpvMEZFWlBzU1ZHODN0UFBEM25zQ1ZzNHNtQVM4M2kzMkptaWhmSlM0aE9qcGtXVnlwUU9hOS1qOTBiT3BFVmdRQy04NlNOUnFQYnctb0NBNHZ3?oc=5","date":"2023-10-05","type":"pipeline","source":"The Cancer Letter","summary":"Ashani Weeraratna and Bill Nelson talk about the early days of cancer research at Johns Hopkins - The Cancer Letter","headline":"Ashani Weeraratna and Bill Nelson talk about the early days of cancer research at Johns Hopkins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1GNXBUT2JpWENRVWdvTjRUVWU2UjZMLVdmVk1YaWdYX3dySHg5a21wSWstaFRjMG9nS3NpQXFYaFFhSmVpWWM0X0NIekNJWHJxa2ZhX1FITXVEMmxZYXVHWUE2QUZxM0lwdERtaUloX0E5Y0JRVmZsZF85d1RlZGs?oc=5","date":"2023-09-08","type":"pipeline","source":"Johns Hopkins Medicine","summary":"Johns Hopkins Kimmel Cancer Center at Green Spring Station - Johns Hopkins Medicine","headline":"Johns Hopkins Kimmel Cancer Center at Green Spring Station","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE5seHFvd0wzdmZJbjYxbUU3eEU0NDlnOG9CODFtVjlhQ29hSk8wNi1vbV9Fek55SWkxWktfeFo5ZFRkRnF4UjVxTXBJZEV6ZzBUT3lIenlUcTdVZw?oc=5","date":"2020-09-25","type":"pipeline","source":"The Cancer Letter","summary":"James Bachman named chief administrative officer of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - The Cancer Letter","headline":"James Bachman named chief administrative officer of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPVlNzcFBLQlV4ODlOdFY5Ylk1SEJJOUlJRU1lN0FlZXRuMXp1dGVlVHFla3Z5R1JCM2JJV05uSmd5NVdRMk04Yi1acktVbHpTUTdXWERVMHBxSk5kWjJVRWpfeDlETW5hcFhZRWR2TDkwNGhqemx5MHZrNnBweXlfeW9sc3BWWE5PdHBoampTTEN3VzdNVTlJaTN6WEszTjVIRktkZlg5U2QyZkZlaFBOSEc2a2w?oc=5","date":"2016-12-05","type":"pipeline","source":"PR Newswire","summary":"AbbVie and Johns Hopkins to Collaborate on Cancer Research - PR Newswire","headline":"AbbVie and Johns Hopkins to Collaborate on Cancer Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9Fdk5PRTdzNWlsUjJjRWNZY0pXUTF1RjlUUmJJM0g4U241WktXOFJkek9Qc0ZKRXZuT1VMa0xvU1NNYkp5RjN1c0RmQzZ2Rlp6REx4MDdsQWRGdE1aZUMzU2stR2dxdXNDYXNONzNPZjV3Zw?oc=5","date":"2014-05-06","type":"pipeline","source":"Johns Hopkins University","summary":"Cancer center at Johns Hopkins to use $65M gift for new patient care building - Johns Hopkins University","headline":"Cancer center at Johns Hopkins to use $65M gift for new patient care building","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_1":2,"marketed":6,"phase_3":2,"discontinued":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}